Scarica l'app Stockscreener
49.08
0.72%
0.295
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HIMS Giù?
Forum
Previsione
Precedente Chiudi:
$48.78
Aprire:
$50.14
Volume 24 ore:
9.83M
Relative Volume:
0.33
Capitalizzazione di mercato:
$10.69B
Reddito:
$1.78B
Utile/perdita netta:
$164.40M
Rapporto P/E:
71.12
EPS:
0.69
Flusso di cassa netto:
$236.51M
1 W Prestazione:
-4.34%
1M Prestazione:
-15.87%
6M Prestazione:
+74.90%
1 anno Prestazione:
+126.09%
Intervallo 1D:
$48.91
$50.19
Intervallo di 1 settimana:
$46.15
$51.36
Portata 52W:
$18.32
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
Nome
Hims Hers Health Inc
Settore
Telefono
415-851-0195
Indirizzo
2269 CHESTNUT ST, SAN FRANCISCO
Confronta HIMS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
49.10 | 11.03B | 1.78B | 164.40M | 236.51M | 0.69 |
|
ZTS
Zoetis Inc
|
147.09 | 64.68B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.19 | 44.25B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.21 | 41.19B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.52 | 21.74B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
420.29 | 18.93B | 3.08B | 1.24B | 1.07B | 25.61 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Downgrade | Needham | Buy → Hold |
| 2025-06-04 | Reiterato | Needham | Buy |
| 2025-04-29 | Downgrade | TD Cowen | Buy → Hold |
| 2025-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Downgrade | Citigroup | Neutral → Sell |
| 2025-01-07 | Iniziato | BTIG Research | Buy |
| 2024-12-17 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-08-22 | Iniziato | Needham | Buy |
| 2024-08-09 | Downgrade | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2024-04-16 | Downgrade | Jefferies | Buy → Hold |
| 2024-04-10 | Iniziato | Canaccord Genuity | Buy |
| 2024-02-28 | Aggiornamento | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2023-12-07 | Iniziato | Imperial Capital | In-line |
| 2023-07-28 | Iniziato | TD Cowen | Outperform |
| 2023-04-11 | Iniziato | Robert W. Baird | Neutral |
| 2023-02-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-08 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-07-15 | Iniziato | SVB Leerink | Underperform |
| 2022-04-14 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | Deutsche Bank | Hold |
| 2021-12-02 | Iniziato | Jefferies | Hold |
| 2021-11-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Iniziato | BofA Securities | Neutral |
| 2021-05-20 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Iniziato | Truist | Hold |
| 2021-03-09 | Iniziato | Credit Suisse | Neutral |
| 2021-03-02 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-02-17 | Iniziato | Citigroup | Neutral |
| 2021-02-12 | Iniziato | Piper Sandler | Neutral |
| 2021-02-08 | Iniziato | Tigress Financial | Buy |
Mostra tutto
Hims Hers Health Inc Borsa (HIMS) Ultime notizie
HIMS vs. LFMD: Which Telehealth Stock Is the Better Investment Now? - Zacks Investment Research
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo
Is Hims & Hers Health Still a Smart Opportunity After 124% Stock Surge in 2025? - Yahoo Finance
Hims & Hers: Pioneering Customer-Centric Innovation with Premium Valuation - FXLeaders
Hims & Hers: Use This Drop Before It's Too Late (NYSE:HIMS) - Seeking Alpha
Hims & Hers Short Interest Nears All-Time High, Buy The Dip? - MarketBeat
Menopause Care Expansion Could Be a Game Changer for Hims & Hers Health (HIMS) - simplywall.st
Shattering the Stigma around Menopause with Molly Sims in New York City - Hims & Hers Newsroom
Telehealth Stock Could Rebound Off Long-Term Trendline - Schaeffer's Investment Research
Hims & Hers: There's Opportunity In This Crash (Upgrade) - Seeking Alpha
Hims & Hers Health, Inc. (HIMS) Stock forecasts - Yahoo
1 Mid-Cap Stock Worth Your Attention and 2 We Avoid - The Globe and Mail
Hims & Hers Health, Inc. (HIMS) Stock Forecasts - Yahoo
Hims & Hers Health, Inc. (HIMS): A Bull Case Theory - Insider Monkey
Why Hims & Hers Stock Slipped Today - AOL.com
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today - Yahoo Finance
Hims & Hers Health Stock (HIMS) Opinions on Menopause Care Launch - Quiver Quantitative
The Problems We’re Solving in Healthcare - Hims & Hers Newsroom
Hims & Hers Advances AI-Powered Personalized Digital Healthcare - Yahoo Finance
Could Hims & Hers Health's (HIMS) Menopause Expansion Reveal a New Competitive Edge in Women's Care? - Yahoo Finance
Hers Launches Menopause and Perimenopause Specialty, Taking the Next Step Toward $1B of Hers Revenue in 2026 - Fitt Insider
Hers Health Inc. stockJuly 2025 Outlook & Fast Entry and Exit Trade Plans - newser.com
Hims & Hers (HIMS) Faces Margin Concerns Amid Growth Plans - GuruFocus
CEO Andrew Dudum Is Ditching Hims & Hers Stock. Should You? - Barchart.com
Hims & Hers rated Sector Weight at KeyBanc on margin worries - Seeking Alpha
HIMS Stock Declines Despite Launch of New Specialty in Women's Health - Yahoo Finance
Hims & Hers Q3 Preview: Key Metrics I Want To See For Beating 2030 Guidance (HIMS) - Seeking Alpha
This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
HIMS: Keybanc Initiates Coverage with 'Sector Weight' Rating | H - GuruFocus
Hers Health Inc. (82W) stock expanding market penetrationPortfolio Update Report & Precise Buy Zone Identification - newser.com
Investor Mood: Hers Health Inc. stock undervalued after correctionLong Setup & Long-Term Safe Investment Plans - nchmf.gov.vn
Hims & Hers: Q3 Could Provide Volatility, But The Long-Term Vision Remains Bright - Seeking Alpha
Hims & Hers CFO Okupe sells $662k in shares - Investing.com
Hims & Hers Health CFO Sells Shares Under Trading Plan - TradingView
HIMS CFO exercises options, sells 11,592 shares under Rule 10b5-1 - Stock Titan
Hims & Hers Health (HIMS) Stock Is Up, What You Need To Know - Yahoo Finance
Hims & Hers Health: Roller Coaster Gift (NYSE:HIMS) - Seeking Alpha
HQY Expands Access With GLP-1 Telehealth & Direct HSA Platforms - Zacks Investment Research
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know - sharewise.com
Hers Health Inc.July 2025 Fed Impact & Technical Buy Zone Confirmations - newser.com
Avoiding Lag: Real-Time Signals in (HIMS) Movement - news.stocktradersdaily.com
Hims & Hers Health (HIMS): How the Menopause Launch Shapes Valuation and Growth Expectations - Yahoo Finance
Should the New Menopause Specialty and CEO Share Sale Prompt a Closer Look at HIMS? - simplywall.st
Why Hims & Hers stock is failing to retain menopause gains and what comes next? - CryptoRank
Trump's Weight-Loss Drug Push May Put These ETFs On A Diet - Benzinga
Hims & Hers CEO sells, analyst calls on Planet Fitness & Deere - Yahoo Finance
Hims & Hers stock sinks amid launch of menopause care - The Business Journals
Hims & Hers Stock Nosedives -- CEO Cashes Out $11 Million Stake - Yahoo Finance
Hims & Hers Health (HIMS) Stock Tanks 15% after CEO Discloses Stock Sale - TipRanks
Hims & Hers Health (HIMS) Stock Declines Following CEO's Major S - GuruFocus
Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom - ts2.tech
Hims Hers Health Inc Azioni (HIMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):